What is RS Research?
Founded in 2015 and headquartered in Turkey, RS Research operates at the intersection of nanotechnology and oncology. The company specializes in the design and development of novel nanomedicines, utilizing innovative drug delivery systems to enhance the efficacy and safety profiles of cancer treatments. By focusing on targeted therapeutic delivery, RS Research addresses significant unmet needs in patient care, aiming to improve clinical outcomes for those battling complex malignancies. The firm's technical foundation is built upon rigorous research and development, positioning it as a high-potential innovator in the biotechnology sector. Its strategic focus on deep-tech drug delivery platforms distinguishes it from traditional pharmaceutical developers, allowing for a more precise approach to oncological intervention.
How much funding has RS Research raised?
RS Research has raised a total of $13.2M across 2 funding rounds:
Private Equity
$1.2M
Series A
$12M
Private Equity (2017): $1.2M with participation from ACT Venture Partners
Series A (2021): $12M led by One life Ventures, GEN Ilaç, and Eczacıbaşı Momentum
Key Investors in RS Research
One life Ventures
One life Ventures is a financial institution based in Mountain View, California, that provides strategic capital to emerging growth companies.
ACT Venture Partners
ACT Venture Partners is a venture capital firm that invests in early stage deep-tech startups, with a focus on AI, IoT, and Big Data analytics.
Eczacıbaşı Momentum
Eczacıbaşı Momentum is the corporate venture capital arm of the Eczacıbaşı Group, focusing on supporting innovative startups in the healthcare and industrial sectors.
What's next for RS Research?
With this major enterprise-level funding, RS Research is well-positioned to transition its lead candidates through critical clinical trial phases. The strategic allocation of these resources will likely prioritize the scaling of manufacturing processes and the strengthening of intellectual property portfolios. As the company matures, the focus will shift toward establishing international partnerships and navigating the regulatory pathways necessary for commercialization. Investors are closely monitoring the firm's ability to translate its nanomedicine research into tangible clinical results, which will be the primary driver for future valuation growth and potential exit opportunities in the global life sciences market.
See full RS Research company page
